Cargando…
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial
Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy f...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190264/ https://www.ncbi.nlm.nih.gov/pubmed/37022196 http://dx.doi.org/10.1128/aac.01419-22 |
_version_ | 1785043249690312704 |
---|---|
author | Vazquez, Jose A. Pappas, Peter G. Boffard, Kenneth Paruk, Fathima Bien, Paul A. Tawadrous, Margaret Ople, Eric Wedel, Pamela Oborska, Iwona Hodges, Michael R. |
author_facet | Vazquez, Jose A. Pappas, Peter G. Boffard, Kenneth Paruk, Fathima Bien, Paul A. Tawadrous, Margaret Ople, Eric Wedel, Pamela Oborska, Iwona Hodges, Michael R. |
author_sort | Vazquez, Jose A. |
collection | PubMed |
description | Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris. Eligible participants were ≥18 years, with established candidemia and/or invasive candidiasis caused by C. auris, (cultured within 120 h [for candidemia] or 168 h [for invasive candidiasis without candidemia] with accompanying clinical signs) and limited treatment options. Participants were treated with FMGX (≤42 days; loading dose: 1000 mg IV twice daily [Day 1], followed by 600 mg IV once daily [QD]). Switching to oral FMGX 800 mg QD was permitted from Day 4. Primary endpoint was treatment success (survival and clearance of C. auris from blood/tissue cultures without additional antifungals) at the end of the study treatment (EOST), assessed by an independent data review committee (DRC). Day 30 survival was a secondary endpoint. In vitro susceptibility of Candida isolates was assessed. Nine participants with candidemia (male:6, female:3; 21 to 76 years) in intensive care units in South Africa were enrolled; all received IV FMGX only. DRC-assessed treatment success at EOST and Day 30 survival were 89% (8/9). No treatment related adverse events or study drug discontinuations were reported. FMGX demonstrated potent in vitro activity against all C. auris isolates (MIC range: 0.008 to 0.015 μg/mL [CLSI]; 0.004–0.03 μg/mL [EUCAST]), with the lowest MICs compared to other antifungals tested. Thus, the results showed that FMGX was safe, well-tolerated, and efficacious in participants with candidemia caused by C. auris. |
format | Online Article Text |
id | pubmed-10190264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-101902642023-05-18 Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial Vazquez, Jose A. Pappas, Peter G. Boffard, Kenneth Paruk, Fathima Bien, Paul A. Tawadrous, Margaret Ople, Eric Wedel, Pamela Oborska, Iwona Hodges, Michael R. Antimicrob Agents Chemother Experimental Therapeutics Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris. Eligible participants were ≥18 years, with established candidemia and/or invasive candidiasis caused by C. auris, (cultured within 120 h [for candidemia] or 168 h [for invasive candidiasis without candidemia] with accompanying clinical signs) and limited treatment options. Participants were treated with FMGX (≤42 days; loading dose: 1000 mg IV twice daily [Day 1], followed by 600 mg IV once daily [QD]). Switching to oral FMGX 800 mg QD was permitted from Day 4. Primary endpoint was treatment success (survival and clearance of C. auris from blood/tissue cultures without additional antifungals) at the end of the study treatment (EOST), assessed by an independent data review committee (DRC). Day 30 survival was a secondary endpoint. In vitro susceptibility of Candida isolates was assessed. Nine participants with candidemia (male:6, female:3; 21 to 76 years) in intensive care units in South Africa were enrolled; all received IV FMGX only. DRC-assessed treatment success at EOST and Day 30 survival were 89% (8/9). No treatment related adverse events or study drug discontinuations were reported. FMGX demonstrated potent in vitro activity against all C. auris isolates (MIC range: 0.008 to 0.015 μg/mL [CLSI]; 0.004–0.03 μg/mL [EUCAST]), with the lowest MICs compared to other antifungals tested. Thus, the results showed that FMGX was safe, well-tolerated, and efficacious in participants with candidemia caused by C. auris. American Society for Microbiology 2023-04-06 /pmc/articles/PMC10190264/ /pubmed/37022196 http://dx.doi.org/10.1128/aac.01419-22 Text en Copyright © 2023 Pfizer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Experimental Therapeutics Vazquez, Jose A. Pappas, Peter G. Boffard, Kenneth Paruk, Fathima Bien, Paul A. Tawadrous, Margaret Ople, Eric Wedel, Pamela Oborska, Iwona Hodges, Michael R. Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial |
title | Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial |
title_full | Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial |
title_fullStr | Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial |
title_full_unstemmed | Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial |
title_short | Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial |
title_sort | clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by candida auris: results from a phase 2 trial |
topic | Experimental Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190264/ https://www.ncbi.nlm.nih.gov/pubmed/37022196 http://dx.doi.org/10.1128/aac.01419-22 |
work_keys_str_mv | AT vazquezjosea clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT pappaspeterg clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT boffardkenneth clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT parukfathima clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT bienpaula clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT tawadrousmargaret clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT opleeric clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT wedelpamela clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT oborskaiwona clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial AT hodgesmichaelr clinicalefficacyandsafetyofanovelantifungalfosmanogepixinpatientswithcandidemiacausedbycandidaaurisresultsfromaphase2trial |